Thrombolysis with alteplase after stroke: extending outcomes
In their fi rst report 1 since publication of the main results, 2,3 the third International Stroke Trial (IST-3) investigators provide new data on the eff ects of alteplase on health outcomes after stroke, and so reignite debate about the best time and method to assess recovery.
90 days is the gold standard time for assessing the eff ects of treatment in acute stroke trials. This window provides a compromise between timely assessment of adverse eff ects and physical recovery and avoidance of the additional costs and logistic diffi culties of longer follow-up. 18 month follow-up in the IST-3 study has several benefi ts. First, fi nding no diff erence in overall mortality (35%) between the groups provides reassurance that alteplase has no long-term adverse consequences related to restenosis of incompletely recanalised intracerebral arterioles. However, the data also suggest that any reduced neurological defi cit from treatment did not translate into a net improvement in medium-term survival. Second, at 18 months, the proportion of patients who were alive and independent was signifi cantly higher in the alteplase group compared with the control group (adjusted odds ratio [OR] 1·28, 95% CI 1·03-1·57; p=0·024). This diff erence was not evident in either the full cohort (1·13, 0·95-1·35; p=0·181) 2 or at 6 months in the participants who were followed up for 18 months (1·18, 0·97-1·45; p=0·10). 1 The consistent between-group distribution of scores on the Oxford handicap scale at 6 months and 18 months suggests that the treatment eff ect was stable but also shows some limitations to the approach.
The Oxford handicap scale score is based on several broad, ordered levels and so it is somewhat insensitive to change over time, can exhibit ceiling or fl oor eff ects, and is limited in its assessment of the functional consequences of stroke on the lives of those aff ected. As a result, health-related quality of life measures are recognised as valid and useful additional endpoints in randomised controlled trials, particularly for treatments that target chronic or disabling diseases. Indeed, medical decision-making increasingly focuses on health-related quality of life as an important variable because many treatments do not cure disease and patients often have an active role in their medical care and are particularly interested in the non-clinical aspects of treatment and their future requirement for care. EuroQoL is a popular generic, preference-based, measure of health-related quality of life because it is simple, concise, and effi cient; it is also able to convert health eff ects into quality-adjusted life-years for evaluations of cost-eff ectiveness.
The large sample size in the IST-3 study (2348 patients assessed at 18 months) overcomes potential biases introduced through the use of proxies (in 54% of patients) to assess health-related quality of life. The fi ndings from the EuroQoL instrument are therefore not only robust, but also off er separate confi rmation of the functional benefi ts of alteplase besides the results of the Oxford handicap scale score. Additionally, they show that recovery from ischaemic stroke continues beyond 6 months-in the patients followed up at 18 months, only ability to self-care and ability to do usual activities were signifi cantly improved at 6 months in the alteplase group. The diff erence between groups in overall health utility score also increased between 6 months and 18 months (from 0·04 to 0·06). Although this change is small, scores ranging from as little as -0·01 to 1·4 are still clinically meaningful. 4, 5 Finally, half of all participants reported at least a moderate degree of www.thelancet.com/neurology Vol 12 August 2013
One of the most frustrating aspects of treating people with epilepsy is the inability to predict who will respond to antiepileptic drugs and who will be treatment resistant. Many theories of treatment resistance have been proposed, including association with disease severity and cause, genetic predisposition, changes in drug targets in the brain, aberrant drug metabolism, and even previous drug exposures during epileptogenesis, [1] [2] [3] all of which could contribute to drug response. Whatever the cause, an individual who has shown resistance to one antiepileptic drug at a reasonable dose has a high likelihood of showing resistance to multiple drugs. In a study of 1098 newly diagnosed patients, failure of the fi rst antiepileptic drug, at 50% or more of the WHOdefi ned daily dose, predicted pharmacoresistance in more than 70% of patients. 4 Upregulation of P-glycoprotein is one mechanism that might account for resistance to multiple antiepileptic drugs. Since many such drugs are substrates of P-glycoprotein, including commonly used treatments such as phenytoin, phenobarbital, lamotrigine, levetiracetam, topiramate, and carbamazepine-epoxide, the overexpression of P-glycoprotein could account for multidrug-resistance. In this issue of The Lancet Neurology, Maria Feldmann and colleagues 5 provide the fi rst in-vivo human evidence of the association between P-glycoprotein overactivity and pharmacoresistance in temporal lobe epilepsy. This was accomplished by looking at diff erences in PET studies with the P-glycoprotein substrate (R)-[ 11 C]verapamil (and in some cases comparing before-and-after infusion of the P-glycoprotein inhibitor tariquidor) in 14 patients with pharmacoresistant temporal lobe epilepsy, eight seizure-free patients, and 13 healthy controls, and showing that the treatment-resistent patients had apparent higher baseline P-glycoprotein activity focally in regions of the hippocampus and temporal lobe.
Upregulation of P-glycoprotein potentially fi ts into many of the hypotheses to explain drug-resistance. There has been speculation that some individuals might have a genetic predisposition for increased expression of P-glycoprotein, due to a polymorphism in ABCB1, the P-glycoprotein transporter gene, 6 which could lead to pharmacoresistance. However, as long as this overexpression occurs thoughout the CNS, these individuals might also be expected to have resistance to side-eff ects involving the CNS, since less of the drug would reach its target. A second scenario is that some causes of epilepsy also produce an upregulation of P-glycoprotein, and in this case upregulation could depression or anxiety during follow-up, emphasising the importance of this comorbidity in adjusting to the eff ects of stroke. 6, 7 I commend the IST-3 investigators for providing a more comprehensive, patient-centred approach to assessment of the eff ects of alteplase on quality of life than has previously been done. As shown in INTERACT2, 8 assessment of health-related quality of life helps the interpretation of outcomes and is an important part of decision-making about effi cacy of treatment that accounts for the patients' perspective.
Craig Anderson
The George Institute for Global Health, Royal Prince Alfred Hospital and the University of Sydney, PO Box M201, Missenden Road, NSW 2050 Australia canderson@georgeinstitute.org.au Peter Sandercock is a member of the data safety monitoring board for a trial that I lead. I collaborate with Richard Lindley, who also has an appointment at the George Institute.
